Premenstrual attacks of acute intermittent porphyria: Hormonal and metabolic aspects - A case report

European Journal of Endocrinology

Volumn 141, Issue 1, 1999, Pages 50-54

  De Block, Christophe E M ^b   De Leeuw, Ivo H ^b   Van Gaal, Luc F ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN DERIVATIVE; GLUCOSE; GONADOTROPIN; HEME ARGINATE; PROPRANOLOL; SYNTEN PATCH TTS; TRIPTORELIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE INTERMITTENT PORPHYRIA; ADULT; ARTICLE; CASE REPORT; CATECHOLAMINE URINE LEVEL; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PARALYSIS; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; TRANSDERMAL PATCH;

EID: 0032814120     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410050     Document Type: Article

References (31)

1. Meyer UA, Strand LJ, Doss M, Rees AC & Marver HS. Intermittent acute porphyria - demonstration of a genetic defect in porphobilinogen metabolism. New England Journal of Medicine 1972 286 1277-1282.
2. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierarch CA et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. American Journal of Medical Genetics 1996 65 269-273.
3. Perlroth MG, Marver HS & Tschudy DP. Oral contraceptive agents and the management of acute intermittent porphyria. Journal of the American Medical Association 1965 194 1037-1042.
4. Watson CJ. Hematin and porphyria. New England Journal of Medicine 1975 293 605-607.
5. McColl KEL, Moore MR, Thompson GG & Goldberg A. Treatment with haematin in acute hepatic porphyria. Quarterly Journal of Medicine 1981 198 161-174.
6. Douer D, Weinberger A, Pinkhas J & Atsmon A. Treatment of acute intermittent porphyria with large doses of propranolol. Journal of the American Medical Association 1978 240 766-768.
7. Anderson KE, Spitz IM, Sassa S, Bardin CW & Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone releasing hormone. New England Journal of Medicine 1984 311 643-645.
8. Elder GH. Hepatic porphyrias in children. Journal of Inherited Metabolic Disease 1997 20 237-246.
9. Grandchamp B, Puy H, Lamoril J, Deybach JC & Nordmann Y. Review: molecular pathogenesis of hepatic acute porphyrias. Journal of Gastroenterology and Hepatology 1996 11 1046-1052.
10. Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ & Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Medica Scandinavica 1978 203 437-443.
11. Suarez JI, Cohen ML, Larkin J, Kernich CA, Hricik DE & Daroff RB. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology 1997 48 1678-1683.
12. Yeung Laiwah AC, Moore MR & Goldberg A. Pathogenesis of acute porphyria. Quarterly Journal of Medicine 1987 241 377-392.
13. Usalan C, Erdem Y, Altun B, Gürsoy M, Celik I, Yasavul Ü, Turgen C & Caglar S. Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clinical Nephrology 1996 45 418.
14. Tshudy DP. Biochemical lesions in porphyria. Journal of the American Medical Association 1965 191 718-730.
15. Schley G, Bock KD, Hocevar V, Merguet P, Rausch-Strooman JG, Schroder E et al. Hochdruk und Tachykardie bei der akuten intermittierenden Porphyrie. Klinische Wochenschrift 1970 48 36-42.
16. Perlroth MG, Tschudy DP, Waxman A & Odell WD. Abnormalities of growth hormone regulation in acute intermittent porphyria. Metabolism 1967 16 87-90.
17. Brozkova V & Topolcan O. Abnormal secretion of thyrotropic hormone and prolactin in acute intermittent porphyria. Casopis Lekaru Ceskych 1984 123 1280-1282.
18. Jusic A, Sostarko M & Majic D. Long-term ACTH and corticosteroid therapy in two siblings with polyneuropathy due to acute intermittent porphyria. European Neurology 1976 14 294-301.
19. Brodie MJ, Moore MR, Thompson GG & Goldberg A. The treatment of acute intermittent porphyria with laevulose. Clinical Science and Molecular Medicine 1977 53 365-371.
20. May BK, Bhasker CR, Bawden MJ & Cox TC. Molecular regulation of 5-aminolevulinate synthase. Diseases related to heme biosynthesis. Molecular Biology and Medicine 1990 7 405-421.
21. Mustajoki P & Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Archives of Internal Medicine 1993 153 2004-2008.
22. Gross U, Honcamp M, Daume E, Frank M, Düsterberg B & Doss MO. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Hormone and Metabolic Research 1995 27 379-383.
23. Wetterberg L, Olsson MB & Alm-Agvald I. Estrogen treatment caused acute attacks of porphyria. Lakartidningen 1995 92 2197-2198.
24. Lindgren A & Olsson R. Liver damage from low-dose oral contraceptives. Journal of Internal Medicine 1993 234 287-292.
25. Andersson C, Bjersing L & Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. Journal of Internal Medicine 1996 240 195-201.
26. Lamon JM, Frykholm BC, Herrera W & Tschudy DP. Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria. Journal of Clinical Endocrinology and Metabolism 1979 48 123-126.
27. Herrick AL, McColl KEL, Wallace AM, Moore MR & Goldberg A. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Quarterly Journal of Medicine 1990 276 355-363.
28. Fraser HM & Baird DT. Clinical applications of LHRH analogues. Clinical Endocrinology and Metabolism 1987 1 43-70.
29. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ & Speizer FE. Early menopause and the risk of myocardial infarction. American Journal of Obstetrics and Gynecology 1981 139 47-51.
30. Aitken JM, Hart DM & Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. British Medical Journal 1973 3 515-518.
31. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 1997 337 1641-1647.